Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting

Catherine Dollfus; Jérome Le Chenadec; Laurent Mandelbrot; Roland Tubiana; Albert Faye; Maud Brossard; Pierre Frange; Stéphane Blanche; Josiane Warszawski; ANRS CO1/CO11 study group

doi:10.1097/INF.0000000000003478

Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting

Pediatr Infect Dis J. 2022 May 1;41(5):420-423. doi: 10.1097/INF.0000000000003478.

Authors

Catherine Dollfus¹, Jérome Le Chenadec², Laurent Mandelbrot^{3

4}, Roland Tubiana^{5

6}, Albert Faye⁷, Maud Brossard^{2

8}, Pierre Frange^{9

10}, Stéphane Blanche¹¹, Josiane Warszawski^{2

8

12}; ANRS CO1/CO11 study group

Affiliations

¹ From the Service d'Hématologie et Oncologie Pédiatrique, Hôpital d'Enfants Armand Trousseau, APHP Sorbonne Université, Paris, France.
² CESP1018, INSERM, Service Epidémiologie-Santé Publique, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
³ Service de Gynécologie-Obstétrique, Hôpital Louis Mourier, APHP Nord Université de Paris, Colombes, France.
⁴ INSERM, UMR1137-IAME, Université de Paris, Paris, France.
⁵ Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, APHP Sorbonne Université, Paris, France.
⁶ INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Sorbonne Université, Paris, France.
⁷ Service de Pédiatrie Générale, Hôpital Robert Debré, APHP Nord Université de Paris, Paris, France.
⁸ APHP, Service de Santé Publique, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
⁹ Service de Microbiologie clinique, Hôpital Necker Enfants-Malades, APHP Centre Université de Paris, Paris, France.
¹⁰ EHU 7328 PACT, Institut Imagine, Université de Paris, Paris, France.
¹¹ Service d'Immunologie Pédiatrique, Hôpital Necker Enfants Malades, APHP Centre Université de Paris, Paris, France.
¹² Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France; and The ANRS CO1/CO11 study group members are listed in the Acknowledgments.

PMID: 35135997
DOI: 10.1097/INF.0000000000003478

Abstract

In the ANRS French Perinatal Cohort, we compared outcomes in 830 HIV1-exposed infants who received either nevirapine (NVP) or zidovudine postnatal prophylaxis. At 1 month, anemia grade ≥2 was less frequent on NVP than zidovudine (2.9% vs. 8.0%; P = 0.01), favoring the use of NVP as a first choice prophylaxis in infants at low risk of HIV acquisition.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents* / therapeutic use
Female
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Infant
Infectious Disease Transmission, Vertical / prevention & control
Nevirapine / therapeutic use
Pregnancy
Pregnancy Complications, Infectious* / drug therapy
Zidovudine / therapeutic use

Substances

Anti-HIV Agents
Zidovudine
Nevirapine